文献速递心脑血管急症

阿替普酶治疗4.5至24小时的后循环缺血性卒中

Alteplase for Posterior Circulation Ischemic Stroke at 4.5 to 24 Hours.
PubMed 文献 · N Engl J Med · 2025-01-01
一句话结论中国后循环缺血性卒中患者(主要为轻型、未取栓)发病4.5至24小时给予阿替普酶,90天功能独立比例高于标准内科治疗(89.6% vs 72.6%)。

这项在中国开展的研究纳入无广泛早期低密度影、未计划取栓的后循环缺血性卒中患者,随机分为阿替普酶组(0.9 mg/kg,最大90 mg)与标准内科治疗组,在发病4.5至24小时给药。主要终点为90天功能独立(改良Rankin量表0至2分),阿替普酶组89.6% vs 标准治疗组72.6%(校正风险比1.16;95%CI 1.03至1.30;P=0.01)。36小时内症状性颅内出血发生率阿替普酶组1.7% vs 标准治疗组0.9%;90天死亡率阿替普酶组5.2% vs 标准治疗组8.5%。作者认为,在未取栓的中国后循环卒中(主要为轻型)患者中,发病4.5至24小时给予阿替普酶较标准内科治疗提高90天功能独立比例。

要点

  • 中国后循环缺血性卒中患者(NIHSS中位3分,四分位距2至6)发病4.5至24小时给予阿替普酶0.9 mg/kg(最大90 mg),90天功能独立89.6% vs 标准内科治疗72.6%(校正风险比1.16;95%CI 1.03至1.30;P=0.01)。
  • 36小时内症状性颅内出血:阿替普酶组1.7% vs 标准治疗组0.9%。
  • 90天死亡:阿替普酶组5.2% vs 标准治疗组8.5%。
  • 入组条件为后循环卒中、CT无广泛早期低密度影、未计划取栓。
  • 共纳入234例,阿替普酶组117例、标准治疗组117例。

适用人群与场景

  • 中国后循环缺血性卒中患者,发病4.5至24小时,CT无广泛早期低密度影,未计划取栓;共234例,阿替普酶组117例、标准治疗组117例,NIHSS中位3分(四分位距2至6)。

诊断标准与关键阈值

  • 功能独立定义为改良Rankin量表评分0至2分(评分范围0至6分,分数越高残疾越重)。

处置流程与药物剂量

  • 阿替普酶0.9 mg/kg(最大剂量90 mg),于发病4.5至24小时给药;对照为标准内科治疗。

红旗征与不能漏的情况

  • 症状性颅内出血:36小时内阿替普酶组1.7% vs 标准治疗组0.9%。

研究设计与关键结果

  • 在中国开展的随机对照试验,纳入234例后循环缺血性卒中患者,阿替普酶组117例 vs 标准治疗组117例,发病4.5至24小时分别给予阿替普酶(0.9 mg/kg,最大90 mg)或标准内科治疗。
  • 主要终点90天功能独立(改良Rankin量表0至2分):阿替普酶组89.6% vs 标准治疗组72.6%(校正风险比1.16;95%CI 1.03至1.30;P=0.01)。
  • 关键安全终点:36小时内症状性颅内出血阿替普酶组1.7% vs 标准治疗组0.9%;90天死亡阿替普酶组5.2% vs 标准治疗组8.5%。

证据类型、等级与局限

  • 随机对照试验(EXPECTS,ClinicalTrials.gov NCT05429476),由中国国家自然科学基金资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在未取栓的中国后循环卒中(主要为轻型)患者中,发病4.5至24小时给予阿替普酶较标准内科治疗提高90天功能独立比例。

指南或共识出处

  • EXPECTS试验,ClinicalTrials.gov NCT05429476,发表于N Engl J Med。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The effects and risks of the use of intravenous thrombolysis between 4.5 and 24 hours after the onset of a posterior circulation ischemic stroke are not well studied.

METHODS: In a trial conducted in China, we randomly assigned patients with posterior circulation stroke, without extensive early hypodensity on computed tomography and with no planned thrombectomy, to receive alteplase (0.9 mg per kilogram of body weight; maximum dose, 90 mg) or standard medical treatment 4.5 to 24 hours after the onset of symptoms. The primary outcome was functional independence (defined as a score of 0 to 2 on the modified Rankin scale; scores range from 0 to 6, with higher scores indicating greater disability) at 90 days. The key safety outcomes were symptomatic intracranial hemorrhage and death.

RESULTS: A total of 234 patients were enrolled; 117 were assigned to the alteplase group and 117 to the standard-treatment group. The median score on the National Institutes of Health Stroke Scale was 3 (interquartile range, 2 to 6) (scores range from 0 to 42, with higher scores indicating greater neurologic deficit). A higher percentage of patients in the alteplase group than in the standard-treatment group had functional independence at 90 days (89.6% vs. 72.6%; adjusted risk ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.30; P = 0.01). The incidence of symptomatic intracranial hemorrhage within 36 hours was 1.7% in the alteplase group and 0.9% in the standard-treatment group. At 90 days, 5.2% of the patients in the alteplase group and 8.5% of those in the standard-treatment group had died.

CONCLUSIONS: Among Chinese patients with mainly mild posterior circulation stroke who did not receive thrombectomy, alteplase administered 4.5 to 24 hours after stroke onset resulted in a higher frequency of functional independence at 90 days than standard medical care. (Funded by the National Natural Science Foundation of China; EXPECTS ClinicalTrials.gov number, NCT05429476.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Yan S, Zhou Y, Lansberg MG, et al. Alteplase for Posterior Circulation Ischemic Stroke at 4.5 to 24 Hours. N Engl J Med. 2025. PMID: 40174223. doi:10.1056/NEJMoa2413344

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。